These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11158756)

  • 1. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.
    Join-Lambert OF; Michéa-Hamzehpour M; Köhler T; Chau F; Faurisson F; Dautrey S; Vissuzaine C; Carbon C; Pechère J
    Antimicrob Agents Chemother; 2001 Feb; 45(2):571-6. PubMed ID: 11158756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
    Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
    Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa.
    Sanz-García F; Hernando-Amado S; López-Causapé C; Oliver A; Martínez JL
    Microbiol Spectr; 2022 Oct; 10(5):e0072322. PubMed ID: 36000896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
    McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
    Ng W; Lutsar I; Wubbel L; Ghaffar F; Jafri H; McCracken GH; Friedland IR
    J Antimicrob Chemother; 1999 Jun; 43(6):811-6. PubMed ID: 10404320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
    Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH
    Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.
    Chidiac C; Roussel-Delvallez M; Guery B; Beaucaire G
    Antimicrob Agents Chemother; 1995 Mar; 39(3):677-9. PubMed ID: 7793872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trovafloxacin.
    Haria M; Lamb HM
    Drugs; 1997 Sep; 54(3):435-45; discussion 446. PubMed ID: 9279505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice.
    Thadepalli H; Reddy U; Chuah SK; Hanna N; Rana G; Gollapudi S
    J Antimicrob Chemother; 2000 Jan; 45(1):69-75. PubMed ID: 10629015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.